CPRiL

4 Functional Relationships(s) Download
	Sentence	Compound Name	Protein Name	Organism
1	In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic.	ibrutinib	Bruton tyrosine kinase	Homo sapiens
2	Consequently, ibrutinib, a BTK-inhibitor, has been studied as a therapeutic option in solid malignancies.	ibrutinib	Bruton tyrosine kinase	Homo sapiens
3	Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer.	ibrutinib	Bruton tyrosine kinase	Homo sapiens
4	Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer.	ibrutinib	Bruton tyrosine kinase	Homo sapiens